Hepatocellular Carcinoma

IRF-1 Expression Arrests Tumor Growth In Vitro And In Vivo

Published in Gene Therapy Weekly, May 10th, 2001

by Deborah W. Heinrich, staff medical writer - Interferon regulatory factor-1 (IFR-1) inhibits hepatocellular carcinoma growth in vitro and in vivo, geneticists report.

A. Kroger and colleagues investigated the use of IFR-1 as an agent for gene therapy in the treatment of highly malignant hepatocellular carcinoma (HCC). They created a fusion protein between IFR-1 and the human estrogen receptor protein (hER), which is activated by beta-estradiol (E2).

Kroger et al. stably transfected IFR-1hER genes into Hepa1-6, an HCC cell line. Before activation with E2, these cells expressed low levels of MHCI, high levels of CD54, and lacked MHCII, CD80, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-05-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry